ifosfamide has been researched along with Cerebral Primitive Neuroectodermal Tumor in 26 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The addition of ifosfamide and etoposide to a standard regimen does not affect the outcome for patients with metastatic disease, but it significantly improves the outcome for patients with nonmetastatic Ewing's sarcoma, primitive neuroectodermal tumor of bone, or primitive sarcoma of bone." | 9.10 | Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. ( Dickman, PS; Donaldson, SS; Fryer, CJ; Gebhardt, MC; Grier, HE; Krailo, MD; Link, MP; Meyers, PA; Miser, JS; Moore, S; Perlman, EJ; Pritchard, DJ; Rausen, AR; Tarbell, NJ; Vietti, TJ, 2003) |
| "Ten children with newly diagnosed medulloblastoma/primitive neuroectodermal tumor of the posterior fossa were treated with total surgical resection, radiation therapy, and ICE chemotherapy regimen with ifosfamide (900 mg/m2, days 1-5), cisplatin (20 mg/m2, days 1-5), and etoposide (60 mg/m2, days 1-5) every 4 weeks for eight cycles." | 7.69 | Combined irradiation and chemotherapy using ifosfamide, cisplatin, and etoposide for children with medulloblastoma/posterior fossa primitive neuroectodermal tumor--results of a pilot study. ( Abe, H; Ikeda, J; Ishii, N; Kato, T; Sawamura, Y; Shirato, H; Tada, M, 1996) |
| "Adding ifosfamide and etoposide to standard therapy does not improve outcomes of patients with Ewing's sarcoma or PNET of bone with metastases at diagnosis." | 5.11 | Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study. ( Dickman, PS; Donaldson, SS; Fryer, CJ; Gebhardt, MC; Grier, HE; Krailo, MD; Link, MP; Meyers, PA; Miser, JS; Moore, S; Perlman, EJ; Pritchard, DJ; Rausen, AR; Tarbell, NJ; Vietti, TJ, 2004) |
| "The addition of ifosfamide and etoposide to a standard regimen does not affect the outcome for patients with metastatic disease, but it significantly improves the outcome for patients with nonmetastatic Ewing's sarcoma, primitive neuroectodermal tumor of bone, or primitive sarcoma of bone." | 5.10 | Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. ( Dickman, PS; Donaldson, SS; Fryer, CJ; Gebhardt, MC; Grier, HE; Krailo, MD; Link, MP; Meyers, PA; Miser, JS; Moore, S; Perlman, EJ; Pritchard, DJ; Rausen, AR; Tarbell, NJ; Vietti, TJ, 2003) |
| "Ten children with newly diagnosed medulloblastoma/primitive neuroectodermal tumor of the posterior fossa were treated with total surgical resection, radiation therapy, and ICE chemotherapy regimen with ifosfamide (900 mg/m2, days 1-5), cisplatin (20 mg/m2, days 1-5), and etoposide (60 mg/m2, days 1-5) every 4 weeks for eight cycles." | 3.69 | Combined irradiation and chemotherapy using ifosfamide, cisplatin, and etoposide for children with medulloblastoma/posterior fossa primitive neuroectodermal tumor--results of a pilot study. ( Abe, H; Ikeda, J; Ishii, N; Kato, T; Sawamura, Y; Shirato, H; Tada, M, 1996) |
| "Median age at diagnosis of Ewing sarcoma was 12 years, and median length of follow-up, 8 years." | 2.73 | Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group. ( Askin, FB; Bhatia, S; Burden, L; Chen, Z; Dickman, PS; Grier, HE; Krailo, MD; Link, MP; Meyers, PA; Miser, JS; Perlman, EJ; Rausen, AR; Robison, LL; Vietti, TJ, 2007) |
| "Consolidation of remissions of pPNET metastatic to bone and bone marrow remains a therapeutic challenge." | 2.68 | Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults. ( Aledo, A; Boland, P; Casper, ES; Gerald, WL; Healey, JH; Heller, G; Kushner, BH; La Quaglia, MP; Meyers, PA; Wollner, N, 1995) |
| "The present case, a CNS PNET, is suspected as a secondary brain tumor induced by radiation therapy previously used to treat a medulloblastoma, and it represents a rare late-onset complication of radiation therapy." | 2.50 | [CNS primitive neuroectodermal tumor suspected as a secondary recurrence after radiation therapy for medulloblastoma:a case report]. ( Endo, S; Kato, S; Koizumi, T; Sato, H; Shibuya, K, 2014) |
| "A primitive neuroectodermal tumor (PNET) is a small round cell tumor that arises from the nerve crest." | 1.36 | Primary Ewing's sarcoma/primitive neuroectodermal tumor of the kidney that responded to low-dose chemotherapy with ifosfamide, etoposide, and doxorubicin. ( Horiuchi, K; Kondo, Y; Mizutani, S; Ohgaki, K; Sato, M, 2010) |
| "The emergence of a primitive neuroectodermal tumor (PNET) within a germ-cell tumor (GCT) is rare." | 1.36 | Outcome analysis of patients with transformed teratoma to primitive neuroectodermal tumor. ( Andreoiu, M; Beck, SDW; Brames, MJ; Cheng, L; Ehrlich, Y; Einhorn, LH; Foster, RS; Ulbright, TM, 2010) |
| "The adverse effects of combination chemotherapy of ifosfamide, cisplatin, and etoposide (ICE) were evaluated in the treatment of various intracranial brain tumors." | 1.36 | [The safety of combination chemotherapy with ifosfamide, cisplatin, and etoposide (ICE): single-institution retrospective review of 108 cases]. ( Kanamori, M; Kumabe, T; Saito, R; Sonoda, Y; Tominaga, T; Yamashita, Y, 2010) |
| "Primitive neuroectodermal tumor (PNET) of the kidney is a rare entity with high malignant potential." | 1.32 | Organ-confined primitive neuroectodermal tumor arising from the kidney. ( Debelenko, L; Granowetter, L; Hensle, TW; Lam, JS; Tennenbaum, SY, 2003) |
| "A case of peripheral medulloepithelioma, a rapidly growing tumor involving the pelvic cavity of a 12-year-old girl, is presented." | 1.32 | Peripheral medulloepithelioma: an immunohistochemical, ultrastructural, and cytogenetic study of a rare, chemotherapy-sensitive, pediatric tumor. ( Donner, LR; Teshima, I, 2003) |
| "Records of 34 patients with ES/PNET who received the IVAD chemotherapy regimens were reviewed." | 1.30 | The use of paediatric chemotherapy protocols at full dose is both a rational and feasible treatment strategy in adults with Ewing's family tumours. ( Fisher, C; Harmer, CL; Judson, IR; Thomas, JM; Verrill, MW; Wiltshaw, E, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (23.08) | 18.2507 |
| 2000's | 12 (46.15) | 29.6817 |
| 2010's | 7 (26.92) | 24.3611 |
| 2020's | 1 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Laskar, S | 1 |
| Sinha, S | 1 |
| Chatterjee, A | 1 |
| Khanna, N | 1 |
| Manjali, JJ | 1 |
| Puri, A | 1 |
| Gulia, A | 1 |
| Nayak, P | 1 |
| Vora, T | 1 |
| Chinnaswamy, G | 1 |
| Prasad, M | 1 |
| Bajpai, J | 1 |
| Juvekar, S | 1 |
| Desai, S | 1 |
| Janu, A | 1 |
| Rangarajan, V | 1 |
| Purandare, N | 1 |
| Shah, S | 1 |
| Rekhi, B | 1 |
| Jambhekar, N | 1 |
| Muckaden, MA | 1 |
| Kurkure, P | 1 |
| Sato, H | 1 |
| Shibuya, K | 1 |
| Koizumi, T | 1 |
| Kato, S | 1 |
| Endo, S | 1 |
| Yoshihara, H | 1 |
| Kamiya, T | 1 |
| Hosoya, Y | 1 |
| Hasegawa, D | 1 |
| Ogawa, C | 1 |
| Asanuma, H | 1 |
| Mizuno, R | 1 |
| Hosoya, R | 1 |
| Manabe, A | 1 |
| Yasuda, K | 1 |
| Taguchi, H | 1 |
| Sawamura, Y | 2 |
| Ikeda, J | 2 |
| Aoyama, H | 1 |
| Fujieda, K | 1 |
| Ishii, N | 2 |
| Kashiwamura, M | 1 |
| Iwasaki, Y | 1 |
| Shirato, H | 2 |
| Ohgaki, K | 1 |
| Horiuchi, K | 1 |
| Mizutani, S | 1 |
| Sato, M | 1 |
| Kondo, Y | 1 |
| Ehrlich, Y | 1 |
| Beck, SDW | 1 |
| Ulbright, TM | 1 |
| Cheng, L | 1 |
| Brames, MJ | 1 |
| Andreoiu, M | 1 |
| Foster, RS | 1 |
| Einhorn, LH | 1 |
| Kanamori, M | 1 |
| Kumabe, T | 1 |
| Saito, R | 1 |
| Yamashita, Y | 1 |
| Sonoda, Y | 1 |
| Tominaga, T | 1 |
| Richey, SL | 1 |
| Rao, P | 1 |
| Wood, CG | 1 |
| Patel, S | 1 |
| Tannir, NM | 1 |
| Sable, S | 1 |
| Gandhi, V | 1 |
| Nagral, A | 1 |
| Nagral, S | 1 |
| Grier, HE | 3 |
| Krailo, MD | 3 |
| Tarbell, NJ | 2 |
| Link, MP | 3 |
| Fryer, CJ | 2 |
| Pritchard, DJ | 2 |
| Gebhardt, MC | 2 |
| Dickman, PS | 3 |
| Perlman, EJ | 3 |
| Meyers, PA | 5 |
| Donaldson, SS | 2 |
| Moore, S | 2 |
| Rausen, AR | 3 |
| Vietti, TJ | 3 |
| Miser, JS | 3 |
| Lam, JS | 1 |
| Hensle, TW | 1 |
| Debelenko, L | 1 |
| Granowetter, L | 1 |
| Tennenbaum, SY | 1 |
| Donner, LR | 1 |
| Teshima, I | 1 |
| Kounami, S | 1 |
| Aoyagi, N | 1 |
| Nakayama, K | 1 |
| Yoshiyama, M | 1 |
| Boshi, H | 1 |
| Sakiyama, M | 1 |
| Takeuchi, T | 1 |
| Yoshikawa, N | 1 |
| Naseri, E | 1 |
| Eralp, B | 1 |
| Oztek, I | 1 |
| Milano, GM | 1 |
| Cozza, R | 1 |
| Ilari, I | 1 |
| De Sio, L | 1 |
| Boldrini, R | 1 |
| Jenkner, A | 1 |
| De Ioris, M | 1 |
| Inserra, A | 1 |
| Dominici, C | 1 |
| Donfrancesco, A | 1 |
| Bhatia, S | 1 |
| Chen, Z | 1 |
| Burden, L | 1 |
| Askin, FB | 1 |
| Robison, LL | 1 |
| Burke, MJ | 1 |
| Walterhouse, DO | 1 |
| Jacobsohn, DA | 1 |
| Duerst, RE | 1 |
| Kletzel, M | 1 |
| Kushner, BH | 2 |
| Gerald, WL | 1 |
| Healey, JH | 1 |
| La Quaglia, MP | 1 |
| Boland, P | 1 |
| Wollner, N | 1 |
| Casper, ES | 1 |
| Aledo, A | 1 |
| Heller, G | 1 |
| Hartley, JM | 1 |
| Hansen, L | 1 |
| Harland, SJ | 1 |
| Nicholson, PW | 1 |
| Pasini, F | 1 |
| Souhami, RL | 1 |
| Kato, T | 1 |
| Tada, M | 1 |
| Abe, H | 1 |
| Verrill, MW | 1 |
| Judson, IR | 1 |
| Wiltshaw, E | 1 |
| Thomas, JM | 1 |
| Harmer, CL | 1 |
| Fisher, C | 1 |
| Yule, SM | 1 |
| Price, L | 1 |
| Pearson, AD | 1 |
| Boddy, AV | 1 |
| Marina, NM | 1 |
| Pappo, AS | 1 |
| Parham, DM | 1 |
| Cain, AM | 1 |
| Rao, BN | 1 |
| Poquette, CA | 1 |
| Pratt, CB | 1 |
| Greenwald, C | 1 |
| Meyer, WH | 1 |
| Skinner, R | 1 |
| Cotterill, SJ | 1 |
| Stevens, MC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective Evaluation of the Prognostic Relevance of PCR Positivity in Blood and Bone Marrow in Non-Metastatic Ewings Sarcoma[NCT00339898] | 414 participants (Actual) | Observational | 2004-03-12 | Completed | |||
| Phase II Study of Cyclophosphamide, Doxorubicin, Vincristine, Etoposide, and Ifosfamide, Followed by Resection and Radiotherapy in Patients With Peripheral Primitive Neuroectodermal Tumors or Ewing's Sarcoma[NCT00002466] | Phase 2 | 0 participants | Interventional | 1990-05-31 | Completed | ||
| Assessment of MGMT Promoter Methylation and Clinical Benefit From Temozolomide-based Therapy in Ewing Sarcoma Patients[NCT03542097] | 82 participants (Actual) | Observational | 2014-04-15 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for ifosfamide and Cerebral Primitive Neuroectodermal Tumor
| Article | Year |
|---|---|
[CNS primitive neuroectodermal tumor suspected as a secondary recurrence after radiation therapy for medulloblastoma:a case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Cisplatin | 2014 |
How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Bone Neopl | 2001 |
8 trials available for ifosfamide and Cerebral Primitive Neuroectodermal Tumor
| Article | Year |
|---|---|
Radiation Therapy Dose Escalation in Unresectable Ewing Sarcoma: Final Results of a Phase 3 Randomized Controlled Trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Fema | 2022 |
Low-dose craniospinal irradiation and ifosfamide, cisplatin and etoposide for non-metastatic embryonal tumors in the central nervous system.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Pr | 2008 |
Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cyclophosp | 2003 |
Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2004 |
High histologic and overall response to dose intensification of ifosfamide, carboplatin, and etoposide with cyclophosphamide, doxorubicin, and vincristine in patients with high-risk Ewing sarcoma family tumors: the Bambino Gesù Children's Hospital experie
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Child; Chil | 2006 |
Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Ch | 2007 |
Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Pr | 1995 |
Chemotherapy dose-intensification for pediatric patients with Ewing's family of tumors and desmoplastic small round-cell tumors: a feasibility study at St. Jude Children's Research Hospital.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 1999 |
16 other studies available for ifosfamide and Cerebral Primitive Neuroectodermal Tumor
| Article | Year |
|---|---|
Ewing sarcoma/primitive neuroectodermal tumor of the kidney treated with chemotherapy including ifosfamide.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Female; Humans; Ifosfamide; Kidney Neoplasms; Magneti | 2016 |
Primary Ewing's sarcoma/primitive neuroectodermal tumor of the kidney that responded to low-dose chemotherapy with ifosfamide, etoposide, and doxorubicin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Doxorubicin; Etoposide; Humans; Ifosfamide; | 2010 |
Outcome analysis of patients with transformed teratoma to primitive neuroectodermal tumor.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosph | 2010 |
[The safety of combination chemotherapy with ifosfamide, cisplatin, and etoposide (ICE): single-institution retrospective review of 108 cases].
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, | 2010 |
Metastatic extraosseous Ewing's sarcoma (EES)/primitive neuroectodermal tumor (PNET) of the kidney: 8-year durable response after induction and maintenance chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Etoposide; Humans; Ifosfamid | 2012 |
Management of a large retroperitoneal primitive neuroectodermal tumour: 'a multimodal approach'.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; | 2012 |
Organ-confined primitive neuroectodermal tumor arising from the kidney.
Topics: Abdominal Pain; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therap | 2003 |
Peripheral medulloepithelioma: an immunohistochemical, ultrastructural, and cytogenetic study of a rare, chemotherapy-sensitive, pediatric tumor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Child; Chromosomes, Human, Pair 2 | 2003 |
Fatal pulmonary thromboembolism after a second course of high-dose chemotherapy with autologous peripheral blood stem cell transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child, Preschool; Cisplatin; Cyclop | 2003 |
Emergency management of severe right ventricular inflow obstruction secondary to a metastatic cardiac tumor.
Topics: Abdominal Neoplasms; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2005 |
Tandem high-dose chemotherapy with autologous peripheral hematopoietic progenitor cell rescue as consolidation therapy for patients with high-risk Ewing family tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Combined M | 2007 |
Metabolism of ifosfamide during a 3 day infusion.
Topics: Adenocarcinoma; Chromatography, Thin Layer; Female; Humans; Ifosfamide; Male; Neuroectodermal Tumors | 1994 |
Combined irradiation and chemotherapy using ifosfamide, cisplatin, and etoposide for children with medulloblastoma/posterior fossa primitive neuroectodermal tumor--results of a pilot study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carboplatin; Cerebellar Neopla | 1996 |
The use of paediatric chemotherapy protocols at full dose is both a rational and feasible treatment strategy in adults with Ewing's family tumours.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; | 1997 |
Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children.
Topics: Adolescent; Antineoplastic Agents; Biotransformation; Brain Neoplasms; Child; Child, Preschool; Cycl | 1997 |
Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Child, Preschool; Cross | 2000 |